West Pharmaceutical Services reported strong Q2 results, beating expectations and raising full-year guidance. The company highlighted broad-based HVP component growth driven by biologics, Annex 1 upgrades, and GLP-1s, while noting a 27% surge in Asia Pacific. Operational improvements and the SmartDose 3.5 divestiture are expected to boost margins in the second half. Q2 revenue $872M (+12.7% organic), adj. EPS $2.37, both above guidance.
Buzzberg readRaised FY2026 organic growth guidance to 10-11%West Pharmaceutical Services reported strong Q2 results, beating expectations and raising full-year guidance. The company highlighted broad-based HVP component growth driven by biologics, Annex 1 upgrades, and GLP-1s, while noting a 27% surge in Asia Pacific. Operational improvements and the SmartDose 3.5 divestiture are expected to boost margins in the second half. Q2 revenue $872M (+12.7% organic), adj. EPS $2.37, both above guidance.Read full analysisCollapse analysis
West Pharmaceutical Services reported strong Q2 results, beating expectations and raising full-year guidance. The company highlighted broad-based HVP component growth driven by biologics, Annex 1 upgrades, and GLP-1s, while noting a 27% surge in Asia Pacific. Operational improvements and the SmartDose 3.5 divestiture are expected to boost margins in the second half. Q2 revenue $872M (+12.7% organic), adj. EPS $2.37, both above guidance.
Full-year FY2026 revenue guidance raised to $3.345-3.38B (10-11% organic); EPS raised to $8.85-$9.05.
HVP components grew 18.4% organic; non-GLP-1 HVP also high teens, driven by biologics and Annex 1 projects (800+ projects, +50% YoY).
Asia Pacific grew 27% organic, led by generic GLP-1 launches in China/India and CDMO demand in South Korea.
Revenue$0.8723B
+3% QoQ
EPS$2.37
+11% QoQ
Gross margin37.74%
reported
Op margin20.53%
reported
What changed this quarter
01
Guidance
Raised FY2026 organic growth guidance to 10-11%
Guidance · revenue to $3.3625B
02
Demand
Non-GLP-1 HVP components grew high teens
Management expressed confidence due to strong Q2 results that exceeded expectations, leading to an upward revision of full-year guidance and highlighting sustained momentum across key growth drivers like biologics and HVP upgrades.
03
Demand
Annex 1 projects up 50% year-over-year to 800
Non-GLP-1 HVP components grew high teens. Management expressed confidence due to strong Q2 results that exceeded expectations, leading to an upward revision of full-year guidance and highlighting sustained momentum across key growth drivers like biologics and HVP upgrades.
04
Other
Completed SmartDose 3.5 divestiture on July 1
HVP components grew 18.4% organic; non-GLP-1 HVP also high teens, driven by biologics and Annex 1 projects (800+ projects, +50% YoY).
Demand & capex
Demand
Bookings & conversion
Non-GLP-1 HVP components grew high teens. Management expressed confidence due to strong Q2 results that exceeded expectations, leading to an upward revision of full-year guidance and highlighting sustained momentum across key growth drivers like biologics and HVP upgrades.
Capex
Investment and capacity
Capital expenditures were $43 million in Q2, down from $75 million last year, as management focuses on capital efficiency. Full-year capex guidance remains unchanged at $250-$275 million, with spending directed toward growth and improved financial returns.
Tone · confident
Management expressed confidence due to strong Q2 results that exceeded expectations, leading to an upward revision of full-year guidance and highlighting sustained momentum across key growth drivers like biologics and HVP upgrades.
Supply-chain alpha
A1
Annex 1 upgrade projects now total nearly 800, up 50% year-over-year, signaling accelerating multi-year conversion of ~6 billion units from standard to HVP components.
“We have just shy of 800 total projects in hand, and that's up 50% from the same time period last year.”
Eschweiler plant achieved double-digit productivity improvements in H1 2026, enabling faster recovery from the May cyber incident and supporting further HVP capacity.
“In the first half of this year we've seen a significant improvement in productivity and throughput and I'll just characterize this as double digit.”
SmartDose 3.5 divestiture closed July 1; management expects it to add 100 bps of margin improvement in H2 2026, offsetting dilutive impact from prior periods.
“SmartDOS 3.5 has been dilutive in the first half of the year... that's 100 basis points in the second half of the year.”
Asia Pacific grew 27% organically, driven by generic GLP-1 launches in China and India, plus increasing CDMO work in South Korea. — Generic GLP-1 entrants in emerging markets are adopting West's high-value components, expanding total addressable market beyond branded GLP-1s.
… the cyber incident as it was not able to fully recover in the quarter, pushing some revenues into the second half of the year. We estimate this was a mid single digit impact to growth in the quarter and is expected to be made up in the remainder of the year. Now, before turning to the rest of the P&L, I wanted to highlight that we delivered double digit growth across each of our three geographies, demonstrating the breadth of our business. Asia Pacific led the way with 27% organic growth as we look to capitalize on the significant market expansion and innovation in that region. Now let's take a closer look at the rest of the P&L. Total company gross margin was 37.7% in the quarter, up 200 basis points year over year. The year-on-year increase was primarily driven by better-than-expected sales and the associated positive mix shift to HVP components as well as price contribution. Of note, we did see a dip in gross margin for our West Vantage business primarily due to the cyber incident, but this was more than made up for by the strong proprietary performance. Adjusted operating margins of 22.6% were up 230 basis points compared to the prior year, driven by the gross margin …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.